PCSK9 and familial hypercholesterolemia: In patients with familial hypercholesterolemia intolerant to statin treatment with either PCSK9 inhibitor did not decrease D-dimer or fibrinogen, which is one of the most robust clinical markers for decreased thrombogenicity [88].